Iltria

Ramipril, the active ingredient in Iltria, is a combination (ACE inhibitor, antiplatelet, HMG‑CoA reductase inhibitor) presented as an oral tablet for oral use. It is employed to manage hypertension, lower cholesterol, and reduce the risk of cardiovascular events in adult patients. It is indicated for patients at elevated cardiovascular risk, including those with a history of myocardial infarction or ischemic stroke.

GNH USA supplies Iltria as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches to meet global demand.

Iltria combines three agents that act on blood pressure, platelet function, and lipid metabolism, addressing major pathways in cardiovascular disease. - Hypertension: lowers systemic blood pressure by inhibiting angiotensin‑converting enzyme, reducing vasoconstriction. - Hyperlipidemia: decreases LDL‑cholesterol synthesis through HMG‑CoA reductase inhibition. - Secondary prevention of myocardial infarction: reduces recurrent cardiac events by antiplatelet action and lipid control. - Secondary prevention of ischemic stroke: lowers risk of repeat stroke via antithrombotic and lipid‑lowering effects. - Overall cardiovascular risk reduction: provides a multifactorial approach to diminish long‑term vascular complications.

Common Side Effects: - Cough: dry, persistent throat irritation. - Headache: mild to moderate intensity. - Gastrointestinal upset: nausea, dyspepsia, or abdominal discomfort. - Dizziness: especially after initial dosing. - Muscle pain: mild myalgia without weakness. - Minor bleeding: bruising or nosebleeds.

Serious or Rare Side Effects: - Angioedema: swelling of face, lips, tongue, or airway. - Severe bleeding: gastrointestinal or intracranial hemorrhage. - Rhabdomyolysis: muscle breakdown with dark urine. - Elevated liver enzymes: indicating hepatic injury. - Anaphylaxis: acute allergic reaction with respiratory compromise. - Thrombocytopenia: marked reduction in platelet count.

Before initiating Iltria, clinicians should evaluate patient history and monitor relevant parameters. - Monitor blood pressure: adjust therapy based on regular measurements. - Assess renal function: check serum creatinine and potassium before and during treatment. - Review hepatic status: avoid in patients with active liver disease. - Evaluate bleeding risk: caution in individuals with a history of ulcers or coagulopathy. - Store at ambient temperature: keep in original container, protect from moisture and light.

Iltria may interact with several concomitant medicines. Major Interactions (Avoid): - Potassium‑sparing diuretics: risk of hyperkalemia. - Lithium: increased lithium serum concentrations. - Strong CYP3A4 inhibitors (e.g., clarithromycin): raise atorvastatin levels and risk of myopathy. Moderate Interactions (Monitor Closely): - Warfarin: may potentiate anticoagulant effect, requiring INR monitoring. - High‑dose NSAIDs: increase bleeding risk.